Anchor Capital Advisors LLC Sells 9,989 Shares of Solventum Corporation $SOLV

Anchor Capital Advisors LLC reduced its stake in shares of Solventum Corporation (NYSE:SOLV) by 1.7% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 587,922 shares of the company’s stock after selling 9,989 shares during the period. Solventum comprises approximately 1.3% of Anchor Capital Advisors LLC’s portfolio, making the stock its 26th biggest position. Anchor Capital Advisors LLC’s holdings in Solventum were worth $46,587,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Hilltop National Bank raised its holdings in shares of Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares during the last quarter. Measured Wealth Private Client Group LLC purchased a new stake in Solventum in the 3rd quarter valued at about $25,000. JNBA Financial Advisors lifted its position in shares of Solventum by 205.4% during the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after buying an additional 228 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new position in shares of Solventum in the 2nd quarter worth approximately $28,000. Finally, City State Bank boosted its stake in shares of Solventum by 166.7% in the 4th quarter. City State Bank now owns 384 shares of the company’s stock worth $30,000 after buying an additional 240 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages recently commented on SOLV. Piper Sandler dropped their price target on Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. UBS Group downgraded Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research note on Thursday, May 14th. BTIG Research reiterated a “buy” rating and set a $89.00 target price on shares of Solventum in a research note on Wednesday, May 6th. Wedbush initiated coverage on shares of Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 price target on the stock. Finally, KeyCorp increased their price target on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Eight equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $84.25.

Insider Transactions at Solventum

In other Solventum news, Director Amy Mcbride Wendell bought 1,475 shares of the stock in a transaction on Tuesday, March 10th. The shares were acquired at an average price of $68.03 per share, with a total value of $100,344.25. Following the acquisition, the director directly owned 5,039 shares of the company’s stock, valued at $342,803.17. The trade was a 41.39% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.24% of the stock is owned by insiders.

Solventum Trading Up 0.7%

Shares of Solventum stock opened at $76.40 on Wednesday. The stock has a market capitalization of $13.23 billion, a P/E ratio of 9.36, a P/E/G ratio of 1.17 and a beta of 0.69. Solventum Corporation has a 52-week low of $62.38 and a 52-week high of $88.20. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The stock’s 50-day simple moving average is $69.75 and its 200 day simple moving average is $75.08.

Solventum (NYSE:SOLV) last issued its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same quarter last year, the business earned $1.34 earnings per share. The company’s quarterly revenue was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.